Drug Discovery World

NOVEMBER 23, 2023

Narain , PhD, President and CEO of BPGbio asks how a better calibre of biobanks in life sciences can lead to more drugs making it to market. Not all biobanks are created equal Biobanks provide a treasure trove of clinical data for exploration with AI tools. But the utility of biobanks varies.

Biobanking 59

Biobanking Drugs Medicine Genome 59

Drug Discovery World

MAY 16, 2024

million development in Manchester intended to enhance the city’s Oxford Road Corridor knowledge quarter as a hub for life sciences and technology innovation. Greenheys at Manchester Science Park is scheduled for completion in Summer 2026 and will span 131,000 sq ft across six floors. Work has started on a £60 ($75.1)

Biobanking 59

Biobanking Development Life Science Genome 59

pharmaphorum

JULY 5, 2022

I recently had the pleasure of attending the PING Conference 2022 , which had the tagline of ‘The Golden Age for Life Sciences Innovation’. Aspirations for the UK in life sciences. So, with all that said, are we really in a golden age for UK life sciences? Reducing complexity across the NHS.

Life Science 98

Life Science Biobanking Medicine Marketing 98

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Generation of strong research dataset cohorts must begin with high-quality clinical samples. Partnerships and Establishing Research Cohorts.

Research 98

Research Biobanking Drugs Genome 98

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. There are different subtypes of heart failure that have different clinical presentations.”. Heart failure affects about 6.2

Development 98

Development Drugs Genome Genomics 98

The Pharma Data

APRIL 11, 2023

BAY 2927088 is a reversible small molecule inhibitor that is currently being evaluated in a first-in-human, Phase 1 clinical trial in non-small cell lung cancer (NSCLC) patients with mutations in epidermal growth factor receptors (EGFR & HER2) including exon20 insertions and point mutations.

Research 40

Research Clinical Trials Clinical Trials Trials 40

Drug Discovery World

OCTOBER 30, 2023

We previously conducted a hypothesis-free study using genotype data from the UK Biobank, which resulted in the first mechanism-based stratification of endometriosis patients. Genomic medicine has therefore had limited impact on improving diagnosis or treatment in endometriosis and other chronic diseases.

Genome 72

Genome Genomics Genotype Clinical Trials 72